The results showed that low expression of TIP30 could lead to a high TNM clinical stage (III or IV clinical stage) in tumor patients (fixed effect model: OR = 2.10, 95% CI: 1.68–2.62) without significant heterogeneity. The gene discussed is HTATIP2; the disease is neoplasm.